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Background: Pain affecting multiple sites on the body is one of the main symp-
toms of fibromyalgia (FM) and it can be a complementary phenotype to other site-
specific pains. The aim of this study was to explore the genetic variants associ-
ated with widespread pain in a cohort of UK Biobank participants who had com-
pleted a pain phenotyping questionnaire. 
Method: Cases and controls were determined by a question answered by UK 
Biobank participants. The question contained 10 selections to identify different 
pain sites around the body. Those selecting ‘pain all over the body’ (9,551) formed 
the case group, and those selecting ‘none of the above’ (232,467) formed the 
control group. Cases were removed based on ancestry information, ethnicity, and 
other possible confounders. 5,670 cases and 149,312 controls met inclusion cri-
teria. A genome-wide association study (GWAS) on pain all over the body was 
performed adjusting with age, sex and body mass index (BMI). The GWAS sum-
mary statistics were then annotated by the online annotation software FUMA. 
Results: Based on the significance level of p < 0.05×10-8, nine GWAS-tagged 
candidate SNPs were found. These SNPs were located in 3 loci. In the first locus, 
the SNP rs17387024 found at the FAF1 gene in chromosome 1 was most signif-
icant with a p-value of 3.72×10-8. In the second locus, the most significant SNP 
was rs550883786 at the intergenic region in chromosome 4 with a p-value of 
3.65×10-8. In the third locus, located at LINC01078 in chromosome 13, the most 
significant SNP was rs148500993, with a p-value of 3.65×10-8. According to re-
lated biochemical researches, FAF1 gene encodes FAF1 (FAS-associated factor 
1) which plays an important role in apoptotic mechanisms by extrinsic and intrin-
sic pathways, and furthermore FAF1 can intervene the sensing of pain indirectly. 
Conclusions: The results suggest that pain all over the body is related to altered 
brain function, and the steps to realise the mechanisms of this relationship lie with 





Chronic widespread pain (CWP), also known as widespread chronic pain (WCP), 
is a chief symptom of fibromyalgia (FM). CWP is a particular type of chronic pain 
in which the pathophysiological causality is not fully understood and cannot be 
simply identified as either neuropathic or musculoskeletal pain. (1) Self-report 
questionnaires may refer to CWP as ‘pain all over the body’1. 
 
1.1. Definition & classification of fibromyalgia (FM) & chronic widespread 
pain (CWP) 
Since the initial categorization of CWP by the American College of Rheumatology 
(ACR) 1990 criteria as a subset of FM, coded as WP1990, the definition of CWP 
has undergone a number of changes and updates. (2) At first, the authors that 
created the criteria sought a pain variable (an early version of widespread pain 
index, WPI) to identify patients with FM. Patients then underwent follow-up ex-
aminations related to tender points, by which the so-called ‘widespread pain’ was 
defined as ‘pain above and below the waist, on both sides of the body and in the 
axial region (see Figure 1-12), and with no exclusions as to the source of the pain’ 
(WP1990) (2, 3). At that time, WP1990 was supplementary to the FM diagnosis 
rather than a separate condition. However, physicians in the following years had 
tended to use such a definition rather widely, to diagnose patients, resulting in an 
increased incidence. By 2015 there were more than 1,500 identified citations to 
CWP, and CWP had also become a discrete entity and subject in many reviews. 
This resulted in appeals for a more precise definition and more prudent applica-
tion of the diagnosis. (4) Though it was frequently used in clinical practice, 
WP1990 was imprecise at times: the number of tender points did not have a strict 
limit (5, 6), and patients with limited somatic pain (i.e., as few as three tender 




2 From https://commons.wikimedia.org/wiki/File:Tender_points_FM.gif 
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definitions. The inherent deficiency of WP1990 led to alternative definitions. (7, 8) 
In 2016, the definition was updated, and the name of CWP was changed into 
‘generalised pain’ in the report in order not to be confused with the previous cri-
teria. The presence of at least four or five body regions was emphasised, which 
tried to tally with FM diagnosis. (7) Experts argue that the definition of CWP 
should not only function as a criterion for FM and could be used outside the con-
text of FM. Meanwhile, there are considerations that CWP should be a single 
diagnostic category and become a hypernym of FM in ICD-11. (1, 9, 10) Never-
theless, it is now still accepted that CWP is a multifactorial pain condition charac-
terised by prolonged pain which lasts for three months or more in multiple regions 
of the body. According to the current criteria, FM diagnosis also requires the 
symptom of CWP as well as significant psychophysiological distress in the form 
of anxiety, anger, frustration, depression, insomnia, and social isolation that can 
be quantified by polysymptomatic distress scale (PSD). (11-15) Table 1-1 lists the 
changes in definition and criteria for FM and CWP respectively since 1990 by 
American College of Rheumatology. (3) 
 








Definition & Details 
 
Code name Definition & Details 
WP1990 
Pain is considered widespread when all the following are present: pain in the 
left side of the body, pain in the right side of the body, pain above the waist, 
and pain below the waist. In addition, axial skeletal pain (cervical spine or 





A patient satisfies the diagnostic criteria for FM if the follow-
ing conditions are met — (1) widespread pain index (WPI) ≥ 
7 and symptom severity score (SSS) ≥ 5 or WPI 3-6 and SSS 
≥ 9; (2) symptoms have been present at a similar level for at 
least 3 months. 
WP2016 
Developed as a widespread pain criterion for FM diagnosis, it is satisfied by 
the presence of pain in four or five body regions. To avoid confusion with the 
WP1990 criteria, it was called ‘generalized pain’ in the 2016 report. 
 
FM2011 





A proposed criterion modified from WP2016 to function as a standalone cat-
egorical measure of CWP. It is satisfied by pain in four or five body regions 
(in effect the WP2016 criterion) in the presence of at least seven painful sites. 
 
FM2016 
A modification of FM2011, FM diagnosis requires (A) WPI ≥ 
7 and SSS ≥ 5 OR a WPI 4–6 and an SSS ≥ 9, (B) presence 
of WP2016, and (C) symptoms of at least 3 months duration. 
 a. A mandatory component of the ACR 1990 FM criteria. 
b. Categorical widespread pain assessment is not contained. 
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1.2. Prevalence of FM & CWP 
FM is generally considered as a common syndrome that appears in clinical prac-
tice and highly impacts the health-related quality of life (HRQoL). There have 
been clinical studies undertaken in various countries, and the prevalence of FM 
in the general population is approximately 3%, ranging from 0.4% to 9.3% world-
wide. (16-18)  
 
In the early surveys, 1990 American College of Rheumatology criteria were al-
most the only source of definition of FM, and the criteria were applied widely. The 
criteria of pain and fatigue listed in Table 1-1 is adapted from the 1990 ACR cri-
teria. According to a research from 1998, the overall prevalence of FM in the adult 
population in the United States was estimated at 2.0% (95% confidence interval 
[CI]: 1.4 to 2.7); prevalence was lower in men (0.5%) than in women (3.4%) and 
increased with age. (19) According to a Canadian community survey, FM affects 
3.3% (95% CI: 3.2 to 3.4) of adults in London, Ontario, being more prevalent in 
women than in men. (8) Similar results of prevalence have been reported in West-
ern European countries, including Germany (3.0%, 95% CI: 1.6 to 4.4), Spain 
(2.4%, 95% CI: 1.5 to 3.2), Italy (2.2%; 95% CI: 1.4 to 3.2), and Sweden (2.5%; 
95% CI not provided) (20-23). Conversely, the prevalence of FM was found to be 
as low as 0.8% (95% CI not provided) in Finland (24) and 0.7% (95% CI: 0.3 to 
1.3) in Denmark (25). Another survey was performed in five European countries 
(France, Germany, Italy, Portugal, and Spain) with the use of LFESSQ-4 (the 
London FM Epidemiology Study Screening Questionnaire, meeting the 4-pain 
criteria alone) and LFESSQ-6 (meeting the 4-pain and 2-fatigue criteria).  
 
Table 1-2 The London FM Epidemiology Study Screening Questionnaire (LFESSQ) used in FM 
prevalence surveys 
Pain criteria 
In the past 3 months: 
1. Have you had pain in muscles, bones, or joints, lasting at least 1 week? 
2. Have you had pain in your shoulders, arms, or hands? On which side? Right, left, or both? 
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3. Have you had pain in your legs or feet? On which side? Right, left, or both? 
4. Have you had pain in your neck, chest or back? 
Meeting the pain criteria requires ‘yes’ responses to all 
4 pain items, and either (A) both a right- and left-side positive response, or (B) a both sides 
positive response. 
Fatigue criteria 
5. Over the past 3 months, do you often feel tired or fatigued? 
6. Does tiredness or fatigue significantly limit your activities? 
Screening positive for chronic, debilitating fatigue requires a ‘yes’ response to both fatigue 
items. 
The estimated overall prevalence of FM was 4.7% (95% CI: 4.0 to 5.3) and 2.9% 
(95% CI: 2.4 to 3.4), respectively, in the general population. The prevalence of 
FM was age- and sex-related and varied among countries. (26) Figure 1-2 depicts 
a bibliographical survey carried out from 2005 to 2014, including 39 studies. The 
2010 American College of Rheumatology criteria had not been widely used yet. 
(27) 
 
A precise definition of FM and CWP has yet to be agreed, which has potentially 
resulted in inaccurate or incomplete diagnosis. In addition, practitioners from dif-
ferent professional specialties (urology, gastroenterology, etc.) tend to make dif-
ferent diagnoses (chronic prostatitis, irritable bowel syndrome, etc.) which are 
referred to as chronic overlapping pain conditions or functional disorders, though 
the symptoms of those patients may share the same pathology. (28) 
 
Figure 1-2 Worldwide distribution of FM prevalence in general population from 2005–2014 
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(Maraques AP et al.) 
 
One method to quantify the epidemiological information of FM is the London FM 
Epidemiology Study Screening Questionnaire (LFESSQ). It is mainly used for 
FM screening in general population surveys of noninstitutionalised adults. (29) 
The details of LFESSQ are shown in Table 1-2. 
 
1.3. Aetiology & pathophysiology of FM & CWP 
The definitions proposed by ACR help to interpret and categorise FM & CWP, but 
the cause of these diseases still remains unclear. (30) Generally, it is hypothe-
sised that the aetiology of FM is a complex interaction of genetic (31) neurological 
(28, 32, 33), immunological (34) and environmental (35) factors. 
 
1.3.1. Related laboratory evaluations 
There is no specific laboratory test for FM. The erythrocyte sedimentation rate 
(ESR) and other inflammatory indices are expected to be normal. The anti-nu-
clear antibodies (ANA) and rheumatoid factors are typically negative and do not 
warrant specific FM screening tests. There might be incidental cases of positive 
results which take place due to the increasing ages of patients. Other diseases 
related to CWP, such as endocrine disorders and Lyme disease, should be con-
sidered during clinical practice and excluded from the diagnosis of FM, while rel-
evant serological tests are not routinely required. (36) 
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1.3.2. Neuroimaging investigations 
The altered central neural processing among patients with FM experience was 
firstly depicted by neuroimaging techniques. (37) The objective information from 
neuroimaging helped to convince the sceptics that pain in FM is ‘real’, and the 
therapeutic rapport between patients and physicians can be ensured. Most com-
mon functional imaging techniques used in FM are single-photon emission com-
puted tomography, functional magnetic resonance, positron emission tomogra-
phy and proton magnetic resonance spectroscopy. 
 
Single-photon emission computed tomography (SPECT) is a nuclear medicine 
tomographic imaging technique using γ rays. SPECT is the first functional neu-
roimaging technique used in FM studies. Guedj et al. found hyper-perfusion of a 
sensitive radioligand (radioactive biochemical substance, a ligand that is radio-
labelled) in the somatosensory cortex, and hypo-perfusion in the cingu-
late, amygdala, medial frontal, and parahippocampal gyrus, and cerebellum. (38)  
 
Functional magnetic resonance (fMRI) supports central augmentation of sensory 
input in FM. (39, 40) The results of the first fMRI study in FM are shown in Fig-
ure1-3 below. (28) In fMRI studies, the brain regions that most strongly encode 
for stimulus intensity are the posterior insula and the secondary somatosensory 
cortices, and these are the brain regions where neuronal activation will be most 
accentuated in individuals with diffuse hyperalgesia or allodynia which encom-
passes symptoms of FM. (41-43) Petzke et al. used fMRI to evaluate the central 
pain processing of patients with FM after the milnacipran treatment, revealing a 
trend of increasing pressure-pain tolerance after the treatment, though it was not 
statistically significant. (44) 
 
Positron emission tomography (PET) aims to measure brain metabolism and 
the distribution of exogenous radiolabelled chemical agents throughout the 
brain. Harris et al used PET to show that the μ-opioid receptors in patients with 
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FM were less available. (45) Wood et al compared patients with FM to healthy 
controls. (46) After noxious intramuscular administration of hypertonic saline in-
fusion, PET showed that only the control group responded to the painful stimuli 
by releasing dopamine in the basal ganglia, which illustrated a lack of response 
in the dopaminergic reward system to stress-induced analgesia. (47) It provides 
objective evidence that patients with FM have an abnormal dopamine response 
to pain. (48) 
 
Figure 1-3 The first fMRI study in FM3 
 
Proton magnetic resonance spectroscopy (1H-MRS) uses natural hydrogen to 
determine the structure of molecules, illustrating how pharmacological and non-
 
3 Individuals with FM (in red triangle) were given a low intensity stimulus (shown in top left panel) and this 
led to moderate pain (a 0–20 Gracely scale was used to rate pain intensity). Their fMRI BOLD responses 
were compared to controls given approximately the same intensity stimulus (blue box) or a higher intensity 
stimulus that was necessary to cause the same amount of pain (green circle). No significant neuronal acti-
vation was shown from this low intensity stimulus in the controls, but there was in patients with FM, and 
these areas of neuronal activation overlapped significantly with the brain activation pattern of the controls 
given nearly twice as much pressure, which was what was required to cause comparable amounts of pain. 
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pharmacological therapies contribute to analgesia among patients. (49) Harris 
et al. investigated 10 patients with FM by 1H-MRS and fMRI before and after a 
non-drug intervention to reduce pain. Validated pain scores were used before 
each imaging session. The changes in glutamate levels measured in the in-
sula reflected changes in pain domains. (50) 
 
In conclusion, there have been various medical imaging studies carried out in 
FM patients, with identified neuropathological pathways supporting the theory of 
central sensitisation. By improving our understanding of the molecular pro-
cesses involved in FM and somatisation disorder, there is the potential to de-
velop novel targeted treatments to improve the prognosis of FM patients. 
 
1.3.3. Concept of central sensitisation 
Hyperalgesia (sensitivity to pain increases abnormally) and/or allodynia (ordinar-
ily nonpainful stimuli elicit pain) can be presented amongst most patients with FM. 
Central sensitisation, an emerging biopsychosocial concept, acknowledge the 
diffuse and widespread nature of the pain as the key feature of FM, and other 
frequent comorbidities such as fatigue, dyssomnia, mood disorder (regarded as 
‘central sensitivity syndrome’) as the abnormal amplification of pain in the central 
nervous system that possibly results in the development of FM. Due to central 
sensitisation, the electrophysiological discharge in sensory processing is pro-
longed, and various forms of stimulation (e.g. smell, noise, chemical exposure, 
etc.) are also exaggerated. It has been discovered that several areas in the cen-
tral nervous system that are responsible for reducing ascending pain transmis-
sion within the spinal cord (e.g., brain stem, cortico-reticular system, locus co-
eruleus and hypothalamus) through the activity of inhibitory neurotransmitters in-
cluding serotonin, norepinephrine, enkephalins, γ-aminobutyric acid and adeno-
sine. (51) In some other chronic pain studies, an imbalance between descending 
inhibitory and facilitatory systems is suggested to contribute to central sensitisa-
tion. (52, 53) 
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1.3.4. Animal models 
Animal models have been developed to emulate the neurobiological process of 
CWP i.e., hyperalgesia and/or allodynia, and models with repeated irritations to 
muscles have become most common and best characterised. Sluka et al. at-
tempted to induce a non-inflammatory pain model by repeated intramuscular in-
jections of acidic saline (pH = 4.0). The model produced widespread hyperalgesia 
of skin, muscle, and viscera while observable tissue damage and inflammation 
were avoided. (54) The model was replicated by other researchers in following 
years (55, 56), and an association was found between the induction of the model 
and a 50-60% incidence of anxiety-like and depression-like behaviours. (57) 
 
Diffuse noxious inhibitory controls (DNIC), also known as conditioned pain mod-
ulation (CPM) is an endogenous pain modulatory pathway which has often been 
described as ‘pain inhibits pain’, which is believed to have relations to the anal-
gesic effects. (58) DNIC has been widely studied in animals.  (59) Different no-
ciceptive conditioning stimuli (electrical stimulation, hot water, acupuncture, or 
pinch) have been used to induce DNIC in animals. (60-62) By blocking the opioid 
receptors in the medullary reticularis nucleus dorsalis, de Resende et al found 
that DNIC increased pain thresholds in uninjured animals and was altered in pain 
conditions. (63) 
 
1.3.5. Genetic factors in FM & CWP 
Significant efforts have been made to uncover the genetic contribution to FM & 
CWP, with potential roles for of a series of candidate genes in the pathogenesis 
of FM. Researchers have attempted to explore the genetic essence of FM by 
assessing the possibility of linkage to the human leukocyte antigens (HLA). Some 
older studies were conducted before the definition and criteria of FM by ACR (i.e., 
WP1990) was devised. Some found statistical significance between HLA region 
and FM. (64, 65) However, such relationships were not confirmed by other studies. 
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(66, 67) The changing diagnostic criteria and different baselines of population 
might lead to inconsistent results. (68) Later, the direction of the research was 
directed to the metabolism of catecholamines, such as receptors of serotonin (68-
70), dopamine (71, 72) as well as norepinephrine. The significant roles of the 
chemicals above in both pain-inhibiting and pain-initiating pathways were likely 
to correlate with FM, and their functions were grounded on the expression of cer-
tain genes and the types of cells. (73, 74) However, the results could not fully 
explain the aetiology of FM. For example, Frank et al. investigated HTR3A and 
HTR3B for sequence variations in patients with FM syndrome with a hypothesis 
that dysfunction of serotonergic neurotransmission could lead to FM syndrome, 
but the data were not statistically significant and the aetiology of FM was yet to 
confirm. (68) Lee et al. conducted a candidate gene study with a sample of 60,367 
total participants from 237 clinics in the US, 2713 of which had been diagnosed 
with FM. The study revealed the associations between demography and FM di-
agnosis in a diverse population as well as some overrepresentations of minor 
alleles which make up the Catechol-O-methyltransferase (COMT) haplotypes 
among the population with FM. However, the COMT haplotypes related to pain 
sensitivity were not directly relevant to FM diagnosis because there were no sta-
tistically significant associations of COMT haplotypes or diplotypes with FM diag-
nosis in the FM group compared to the non-FM group. (75)  
 
Other candidate genes of certain nociceptive neurotransmitters like substance P 
(SP) have also been investigated. In early studies, SP was explicitly shown to be 
elevated in level in the cerebral spinal fluid (CSF) among FM patients (76). SP 
was also postulated to be involved in chronic stress response and pain signalling 
because it was one of the old neuropeptides in a view of phylogenetics (77, 78). 
Ablin et al. conducted a candidate gene study in the year of 2009 of the 1354 
G>C polymorphism in the TACR1 (substance P receptor) but the result did not 
reach the criteria of statistical significance. (79) Nevertheless, serological re-
search conducted in 2016 showed that substance P along with corticotropin-
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releasing hormone (CRH) and SP-structurally-related hemokinin-1 (HK-1) had el-
evated levels in FMS patients compared with healthy controls, suggesting that 
these molecules could be released centrally and may cause focal inflammation 
leading to activation of mast cells, while peripheral inflammation may still have 
central effects. When mast cells were stimulated, they secreted inflammatory cy-
tokines (IL-6 and TNF) that contribute to the symptoms of FMS. The authors sug-
gested the treatment directed at preventing the secretion or antagonising these 
elevated neuroimmune markers, both centrally and peripherally. (80) 
 
Genome-wide association study (GWAS) is a revolutionary technique that has 
dramatically increased the capacity to study the genetic basis of complex traits, 
including the fields in FM and chronic pain. However, it is still difficult for GWA 
studies to identify loci that can fully clarify the heritable component. Rare variants 
possibly result in complex traits and identified loci can only explain a small portion 
of them. (81) Family-based designs of genetic studies were proved to be useful 
to detect genetic variants with a large effect size, which tend to be rare in the 
population, but they are more frequent in cohorts of multi-case families. Using 
this strategy, Arnold et al. genotyped members of 116 families from the FM family 
study and a model-free genome-wide linkage analysis of FM syndrome with 341 
microsatellite markers was performed. (82) The study recognised chromosome 
17p11.2–q11.2 region as a possible major locus for FM syndrome. In particular, 
the region coincides with two potential candidate genes of FM, viz TRPV2 (tran-
sient receptor and the vanilloid channel 2 gene) and SLC6A4 (serotonin trans-
porter gene), while other candidate genes, including COMT, are irrelevant to the 
region. (83) 
 
Peters et al. have performed a GWAS of CWP, not specifically FM. (84) In the 
research 1,308 female patients suffering from CWP were tested, along with 5,791 
controls. The study also replicated the effects of the genetic variants with evi-
dence for relevance to 1,480 CWP cases and 7,989 controls. The results 
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demonstrated a genetic variant on chromosome 5p15.2 associated with CWP, 
which is located upstream at the gene CCT5 (chaperonin-containing-TCP1-com-
plex-5 gene) and downstream at FAM173B (also ATP synthase c subunit lysine 
N-methyltransferase, ATPSCKMT). The authors remarked that both these genes 
could be promising targets in the regulation of pain. There were other previous 
researches that could support the findings in the GWAS. A research in a human 
pedigree showed that the mutation in CCT5 gene could cause hereditary sensory 
neuropathy, as known as ‘autosomal recessive mutilating sensory neuropathy 
with spastic paraplegia’. (85) Pain was one of the observed symptoms in the re-
search. Kubota H et al expounded the biochemical functions of CCT5 that CCT5 
assisted in folding and assembly protein in the brain as a subunit of the chap-
eronin containing t-complex polypeptide 1 (TCP-1). (86) Małecki J et al. used 
bioinformatics analyses and biochemical assays to determine the functions of 
FAM173B, and uncovered that FAM173B contained an atypical, non-cleavable 
mitochondrial targeting sequence responsible for its localisation to mitochondria. 
They also identified FAM173B as the long-sought KMT (mitochondrial lysine-spe-
cific methyltransferase) responsible for methylation of ATPSc (ATP synthase c-
subunit), a key protein in cellular ATP production, and demonstrated its influential 
function of ATPSc methylation. (87) 
 
Overall, the results were scarcely concordant with each other due to the limited 
sample size and sparse replication. Generally, candidate gene studies are often 
biased by previous hypotheses and non-genetic proofs. There is still a lack in the 
pathophysiological knowledge about CWP, which increases the chances of in-
consistent results and reduces the chances of success. 
 
1.3.6. Personality factors in FM & CWP 
The personality of patients with FM & CWP is one of the subjects that arouse 
much controversy. Some researches revealed specific traits, (88, 89) but others 
argued that those traits were not differentiated from the normal population. (90) 
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It is also considered that certain emotional regulation deficits instead of particular 
traits characterised FM. (91) Historically, patients with FM have been perceived 
to be close to Cluster B personality disorders (PDs, e.g. dramatic, impulsive and 
emotional), while emotional dysregulation or self-regulation deficit could help to 
interpret the similarity. Meanwhile, FM patients show a high level of psychopathol-
ogy and childhood trauma, as in borderline personality disorder (BPD). (91) 
 
Figure 1-4 The Big Five personality traits (OCEAN model) 
 
Based on the Big Five personality traits (also known as OCEAN model) (see Fig-
ure1-4), the Big Five Inventory is one the powerful tools to detect the personality 
factors in social sciences. (92) It also helps to uncover the personality factors that 
intervene in the emotional regulation and modulation of pain. Bucourt et al. used 
the Big Five Inventory to analyse the personality factors of 163 women with FM, 
rheumatoid arthritis, spondyloarthritis and Sjögren’s syndrome. (93) Patients with 
FM had higher scores on agreeableness, neuroticism, and openness than those 
with other rheumatic diseases, which highlighted the specificity of personality in 
FM. 
A systematic review conducted by C Conversano et al. found that many studies 
underline high levels of alexithymia and type D personality in FM patients, but 





1.3.7. Psychosocial stressors related to FM & CWP 
As a main feature of CWP, pain all over the body is of great genetic susceptibility, 
and yet its development may also be involved with environmental factors. Early-
life events, such as physical trauma and psychosocial stressors have been found 
to interfere in the genetic expression and further contribute to the occurrence. (94, 
95) 
 
Studies have been investigating the earliest stage childhood that can form long-
term psychological and behavioural alterations. Physical trauma in early life has 
been proved as a significant factor. Early and childhood experiences, when well 
quantified and evaluated, have been related to enduring changes in nociceptive 
circuitry and increased pain sensitivity in older organism. (96) For instance, prem-
ature delivery (97) and sexual abuse (98) may contribute to change the pain 
threshold in adulthood and trigger the development of CWP. (96) Genetic re-
searches also help to elucidate the mechanism. A gene named MAOA (monoam-
ine oxidase A gene) has been shown to alter the effect of childhood maltreatment 
at risk of antisocial behaviours. As a result, there could be a rise in the impairment 
of HPA (hypothalamic-pituitary-adrenal) axis, and the response to stress could be 
less efficient subsequently and the patients are much more sensitive to pain 
and/or fatigue. 
Repeated physical stressors among adults have also been demonstrated to be 
involved in the development of CWP. Mechanical injury, resulted from activities 
like heavy lifting, repetitive motions, or squatting for extended periods of time in 
the workplace, plays an important role in the onset of CWP. (99) 
 
Meanwhile, researches pointed out that psychosocial stressors seem to be the 
environmental triggers of CWP, and emotional trauma is another strong predictor 
of the disease in addition to physical trauma. (100, 101) A study in 2005 offered 
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a snapshot of FM among a self-selected population by an Internet survey, and 
the result was heuristic that emotional precipitants might trigger FM and/or low 
back pain. (102) Emotional abuse, post-traumatic stress disorder (PTSD) and 
other negative environmental conditions are basic characteristics of childhood 
maltreatment which has been recently discovered to affect FM in another self-
reported research. Interestingly, these patients with FM had significantly higher 
concomitant levels of depression and anxiety. (103) Chang et al. conducted a 
nationwide longitudinal study and demonstrated a bidirectional temporal associ-
ation between FM and depression, implying their shared pathophysiology. (104) 
To support the connection, the morphometric study of altered white and grey mat-
ter including medial orbitofrontal cortex and cerebellum was conducted among 
patients with FM, and the volume of grey matter was found to be related to the 
severity of hyperalgesia and depression. In addition, the number of fibres in white 
matter between specific submodule regions was also related to measures of 
educed pain sensitivity and clinical pain interference. (105) 
 
Stressful life events in patients with FM demonstrated the transcultural robust-
ness in relation to retrospective self-reports of childhood maltreatment and life-
long traumatic experiences. (106) There is little tangible evidence of physiological 
processes mediating the connection between the occurrence of FM/CWP and 
experiencing stress. (107) The hypothalamic-pituitary-adrenal (HPA) axis may in-
fluence this relationship: the increased pain levels have been found to be related 
to the failure of HPA axis and decreased levels of hypothalamic corticotrophin-
releasing hormone in the cerebrospinal fluid (CSF). (108) 
 
1.4. Management of FM & CWP 
FM is regarded as one of the medically unexplained physical symptoms (MUPS), 
whose cause remains contested. Thus, a multimodal approach is recommended 
to be established. (109) Meanwhile, there is a lack of high-quality randomised 
controlled trials (RCTs) demonstrating convincing efficacy. 
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Treatment for FM typically encompasses symptom management, alleviating pain, 
and other comorbidities. Development in the comprehension of the pathophysi-
ology of the disorder have led to improvement in treatment, which may include 
prescription medication, behavioural intervention, and exercise. In practice, mul-
tidisciplinary care is utilised, for instance, comprised of medication, aerobic exer-
cise, cognitive behavioural therapy, etc. have been shown to be effective in alle-
viating pain and other FM-related symptoms. (110, 111) 
 
1.4.1. Medication 
Antidepressants are used to treat major depressive orders, some anxiety disor-
ders, some chronic pain conditions, and to assist in managing addictions. (112) 
It is reported that antidepressants are ‘associated with improvements in pain, de-
pression, fatigue, sleep disturbances, and health-related quality of life in people 
with FM syndrome’. (113) The chief goal of antidepressants should be symptom 
reduction and their effects should also be evaluated against side effects. Placebo-
controlled clinical trials have shown that a small number of subjects can benefit 
significantly from the serotonin–norepinephrine reuptake inhibitors (SNRIs), for 
example, duloxetine and milnacipran as well as the tricyclic antidepressants 
(TCAs, e.g., amitriptyline). (114-117). However, many people also encountered 
adverse events during or after the medication. Evidence is of limited quality that 
the benefits and harms of selective serotonin reuptake inhibitors (SSRIs) appear 
to be similar. (118) SSRIs may be used to treat depression in people diagnosed 
with FM. (119) Tentative evidence suggests that monoamine oxidase inhibi-
tors (MAOIs) such as pirlindole and moclobemide are moderately effective for 
reducing pain. Very low-quality evidence implies that pirlindole is more effective 
at treating pain compared with moclobemide. Side effects of MAOIs may include 
nausea and vomiting. (120)  
 
Anticonvulsants (also commonly known as antiepileptic drugs or as antiseizure 
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drugs) are used in the treatment of epileptic seizures. Anticonvulsants are also 
used in the treatment of bipolar disorder (121) and neuropathic pain (122). Some 
anticonvulsants such as pregabalin and gabapentin demonstrate a small benefit 
over placebo in alleviating pain and sleep problems in FM. (123) Derry et al. found 
that pregabalin was able to produce a major reduction in pain intensity over 12 to 
26 weeks with tolerable adverse events for a small proportion of people (about 
10% more than placebo) with moderate or severe pain due to FM, which resem-
bles the results of other researches in SNRIs (124, 125). Meanwhile, more par-
ticipants experienced an adverse event with pregabalin (65% with pregabalin vs. 
49% with placebo). (126) In another study, provisional evidence shows that 
gabapentin may be useful for pain in about 18% of people with FM, (127) but it is 
still difficult to anticipate who will benefit. Cases of side effects such as vertigo 
also occur among people who take gabapentin. (128) There are also increasing 
concerns around the abuse potential of gabapentinoids and association with drug 
deaths. (129) 
 
It is controversial to use opioids to treat FM; though opioids are used worldwide, 
the U.S. Food and Drug Administration (FDA) does not generally approve their 
use in this condition, (130) and opioids scarcely take effect. (131) Authorities have 
concern for the misuse of opioids in FM treatment especially when there are al-
ternative medications to control the pain. They suggest that people using opioids 
should be placed under surveillance by healthcare providers to prevent side ef-
fects and possible unwanted drug behaviours. (132) Long term use of opioids is 
not currently recommended for the treatment of chronic pain4. 
 
In addition to the aforementioned medications, there are other types of drugs ap-
plied to FM treatment. A systematic review in 2014 revealed a possible connec-
tion between the disturbances of the proportion of growth hormone (GH) to 
 
4 See https://www.iasp-pain.org/Advocacy/Content.aspx?ItemNumber=7194 
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insulin-like growth factor 1 (IGF-1) and the occurrence of FM syndrome. (133) 
Sodium oxybate increases growth hormone production levels through increased 
slow-wave sleep patterns. However, this medication was not approved by the 
FDA for the indication for use in people with FM due to the concern for abuse. 
(134, 135) The use of NSAIDs are not recommended as the first line therapy. 
(136) NSAIDs are not regarded to be useful in the management of FM. (137) 
 
1.4.2. Non-pharmacological treatment 
The non-pharmacological treatment together with the related therapies is an ap-
plication of psychosomatic medicine to resolve the problem of FM. Cognitive be-
havioural therapies (CBTs) include interventions that are based on the basic 
premise that chronic pain is maintained by cognitive and behavioural factors, and 
that psychological treatment leads to changes in these factors through cognitive 
(e.g., cognitive restructuring) and/or behavioural (e.g., relaxation training, social 
skills training) techniques. Different types of CBTs can be differentiated by the 
techniques applied. 
 
As a non-pharmacological component of the management of FM, CBTs and re-
lated therapies have a small to moderate effect in reducing FM symptoms. (138) 
CBTs have been recommended for FM management by recent evidence-based 
guidelines. (125, 139) Internet-based cognitive psychological therapies (ICBTs), 
a subset of CBTs, are a growing area of mental health, because they are cost-
effective and almost all-pervading in many somatic and psychological disorders. 
(139)  
 
A systematic review and meta-analysis of the efficacy of CBT in FM was per-
formed, including 14 trials with 910 subjects with a median treatment time of 27 
hours. Though the positive effect on depressed mood was not identified with pos-
sible risks of bias, there was a significant effect on self-efficacy pain post treat-
ment, and the ‘healthcare-seeking behaviour’ was also reduced (subjects 
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reduced the frequency to see physicians at follow-up). (140) 
 
In addition to CBTs, mind-body therapy is an increasing social and clinical trend, 
which focuses on interactions among the brain, mind, body and behaviour. (141) 
It is a synthesis of biofeedback, psychological and physical interventions. Psy-
chological interventions are slightly effective in the treatment of FM, but the sus-
tained effectiveness of mind-body therapy remains to be substantiated (142, 143) 
 
There is strong evidence indicating that exercise improves fitness and sleep and 
may reduce pain and fatigue in some people with FM. (144, 145) Low-quality 
evidence from heterogenous trials suggests that high-intensity resistance training 
may improve pain and strength in women. (146) Studies of different forms of aer-
obic exercise for adults with FM imply that aerobic exercise improves quality of 
life, reduces pain, slightly improves physical function and yet makes no difference 
in fatigue and stiffness. (147) In terms of combinations of exercises, Bidonde et 
al investigated randomised controlled trials (RCTs) in adults with a diagnosis of 
FM that compared mixed exercise interventions with other or no exercise inter-
ventions. (148) They found that combinations of different exercises such as flex-
ibility and aerobic training may improve stiffness, but the improvement may be of 
less clinical importance for some participants, and it remains uncertain whether 
the long-term effects can be maintained. Table 1-3 summarises different types of 
management of FM. 
Table 1-3 Summary of management of FM 
Types of management Examples Notes 
Medication Antidepressants SSRIs (Duloxetine, 
milnacipran, etc.) 
Adverse effects (dizziness, etc) 
may occur. Benefits are some-
times limited.   TCAs (amitriptyline, etc) 
  MAOIs (Pirlindole, mo-
clobemide, etc.) 
 Anticonvulsants Pregabalin, gabapentin, 
etc 
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 Opioids  Effective but not recommended 
(with possibility of substance 
abuse) 
 Others Sodium oxybate Not recommended by FDA 
 NASIDs Not useful 
Therapy CBTs ICBTs, Mindfulness-




 Mind-body therapy Slightly effective 
Exercise Aerobic exercise, flexibility exercise, re-
sistance exercise, etc. 
Less clinically important to some 
patients; long-term effects not 
found 
 
1.5. Introduction to the UK Biobank 
The UK Biobank is a major national and international health resource as well as 
a registered charity. It is established with the aim of improving the prevention, 
diagnosis, and treatment of a wide range of diseases. Five hundred thousand 40-
69-year-old people were recruited across the UK by the project from 2006 to 2010. 
All participants gave informed consent for their data to be used for research pur-
poses. Samples of blood, urine and saliva are stored for future analysis. Details 
of the UK Biobank resource can be found at www.ukbiobank.ac.uk. Figure 1-5 




Figure 1-5 Summary of the UK Biobank resource and genotyping array content (Bycroft C et al.) 
 
 
1.5.1. The UK Biobank Axiom genotyping array 
The UK Biobank Axiom array from Affymetrix is a widely adopted platform for 
large-scale biobank genotyping studies. It was specifically designed for geno-
typing the UK Biobank participants. There are around 800,000 markers on the 
array. The design concept was basically categorized into three parts: (a) to add 
markers of particular interest based on known associations and/or possible 
roles in phenotypic variation; (b) to add coding variants across a range of minor 
allele frequencies (MAFs), principally missense and protein truncating variants; 
(3) to choose the remaining content to provide good genome-wide imputation 
coverage in European populations in the common (> 5%) and low frequency (1-
5%) MAF ranges. 
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For GWA studies, Axiom array content modules are able to provide intelligent 
marker selection which enables imputation of millions of additional SNPs. The 
genomic content module of each array is also optimised for specific populations 
and is customisable to any 1000 Genomes population study by adding addi-
tional markers dependent on the specific research focus. 
 
1.6. Objective of the study 
The purpose of this study is to identify the genetic variants related to CWP (‘pain 
all over the body’). We conducted a genome-wide association study (GWAS) us-




2.1. Basics of GWAS 
Genome-wide association study (GWA study, or GWAS), also known as whole 
genome association study (WGA study, or WGAS), aims to explore/examine as-
sociations between genetic variants (single nucleotide polymorphisms, SNPs) 
and major human diseases on a scale of whole genome set. This method is a 
type of observational study and entails the correspondence of a given human 
genome sequence with a fully interpreted map of common genetic variation. 
When a study focuses on a large population with well-defined clinical character-
istics and a large collection of DNA samples is provided, GWAS is a powerful 
research tool. By sifting out relevant genes, GWAS is providing us with a new 
realm of understanding that individuals are predisposed towards certain diseases 
due to genetic variations. 
 
GWAS is theoretically based on the linkage disequilibrium (LD), a non-random 
relation of alleles at different loci in a given population. In other words, SNP alleles 
or DNA sequences that are close together in the genome tend to be inherited 
together. Once the patterns of LD are known, alleles can play roles as markers, 
either individually or collectively, to distinguish one region from another, and thus 
fewer SNPs can capture more common variations within the regions. Besides, 
the possible SNP variants are so many that it is still very expensive to sequence 
all SNPs, and the feasible way is to set up customisable arrays to genotype a sub 
set of the variants. For instance, there are more than eight hundred thousand 
SNPs in the bespoke Affymetrix UK Biobank gene chips used in this study, and 
all variants of the genome can virtually be tagged. If a SNP is related to a trait or 
a disease, then the actual biological effect will be brought forth by one of the 
variants that the SNP stands for, including that SNP itself.  
 
Since GWA studies aim to investigate the whole genome, it is a method not driven 
by any candidate genes, in contrast with other genetic methods that specifically 
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test a small number of pre-specified genetic regions. Candidate genes are most 
often selected for study based on a priori knowledge of the biological functional 
impact of gene on the trait or disease in question. (150) Candidate genes are 
often confined within a small number of genetic regions. If the previous research 
has flaws or fails to be replicated, then the candidate genes deduced from it will 
be questioned. GWAS can avoid that limitation. On the other hand, GWA studies 
cannot deduce on their own which genes are causal, while they are able to iden-
tify SNPs and other variants in DNA related to a certain disease. 
 
Figure 2-1 General classification of GWA studies 
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2.1.1. GWAS based on unrelated individuals 
There are two types of designs when targeting unrelated individuals (see Figure 
2-1): case-control studies and population-based association studies. The former 
is mainly used to study qualitative traits (whether it is diseased) while the latter is 
generally to discover quantitative traits. Various statistical approaches are used, 
which depends on the study design and the phenotype. For instance, a case-
control study design (quality traits), comparing the allele frequency of each SNP 
between the case and the control group can be performed using a 2 x 2 chi-
squared test to calculate the odds ratio (OR) and its 95% confidence interval (CI). 
The attributable fraction (AF) as well as attributive risk (AR) can also be calcu-
lated. Logistic regression is also used when adjustments are made to avoid con-
founding factors e.g., age, sex, and ethnicity. The general process is to regard 
the occurrences of diseases as the dependent variable, and the genotypes as 
well as confounding factors as independent variables. The study design is often 
based on a random population (quantitative traits), such as investigating the as-
sociation between SNPs and the quantitative phenotypes of a disease (BMI, etc.). 
It is common to compare whether the levels of the phenotype among the geno-
type carriers at the locus are different (one-way ANOVA). Confounding factors 
probably need to be adjusted by introducing covariance analysis or linear regres-
sion equations. 
 
2.1.2. Multiple test adjustment in GWA studies 
The statistical issue of multiple testing is one of the greatest problems that con-
tribute to potential false-positive results because of the massive numbers of 
SNPs. (151) The common methods for multiple test corrections are generally 
consolidated into the software for genetic statistics (see Figure 2-2). 
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Figure 2-2 Common methods of multiple testing corrections 
 
The Bonferroni correction compensates for the increasing likelihood of rejecting 
a null hypothesis incorrectly (i.e., making a Type I error) by testing each individual 
hypothesis at a significance level of !", where " represents the desired overall 
alpha level and # represents the number of hypotheses. (152) The Bonferroni 
correction receives criticism of the conservative trait since there are too many 
times of comparisons and the test statistics are positively correlated. The false-
negative rate is usually high. 
 
The Holm-Bonferroni method is intended to control the family-wise error rate 
(FWER) and offers a simple test uniformly more powerful than the Bonferroni 
correction. (153, 154) The basic procedure is as follows: By ordering correspond-
ing p-values from lowest to highest ($#, $$, … , $"), the associated hypotheses are 
assumed to be '#, '$, … , '". For a given significance level ", let ( be the min-
imal index such that $% > !"&%'#. Then reject the null hypotheses from '# to 
'%&# and do not reject the rest ('% , '%'#, … , '"). Specially, all hypotheses are 
rejected if ( = 1. The method ensures that FWER is not more than ". Like Bon-
ferroni correction, the Holm-Bonferroni method adjusts the p-values separately. 
It requires software and advanced methods to calibrate p-values simultaneously. 
 
The Westfall-Young permutation takes strongly dependent test-statistics into ac-
count. (155) The basic operation is to sort out the uncorrected p-values at first, 
and then repeat sampling simulations based on the structural relationship 
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between genes. After analysing the distribution of p-values, correct all p-values 
simultaneously. 
 
The Benjamini-Hochberg procedure aims to decrease the false discovery rate 
and control the p-values still further. (156) The basic procedure is as follows: By 
ordering corresponding p-values from lowest to highest, keep the largest p-value 
and multiply others by certain coefficients (amount of loci/order of the p-value). If 
the adjusted p-value is smaller than the given significance level ", then the locus 
makes a significant contribution to the disease. The Benjamini-Hochberg proce-
dure is one of the least strict corrections of p-values, which would cause more 
false positive cases. 
 
2.1.3. Limitations in GWAS 
GWAS opens a new chapter in the study of complex diseases: researchers do 
not need to presuppose any strategies for candidate genes, but instead compare 
the allele frequency of all the genome-wide mutations in cases and controls and 
find disease-related sequence variation. GWAS has discovered many unknown 
genes and chromosomal regions that we have not known previously, providing 
more clues for us to understand the pathogenesis of complex human diseases. 
However, we cannot be too optimistic about the role of GWAS in the aetiological 
studies of complex diseases. To find SNPs which are truly related to complex 
diseases, GWAS requires the following conditions: the case group of the GWAS 
sample must carry the genetic factors resulting in the disease; the research needs 
to achieve a sufficient test power; the sample size and the number of SNPs are 
very large; a large number of human SNPs need to be genotyped in thousands 
of cases and controls. Data analysis also requires more advanced statistical 
methods. (151) 
Sometimes, even if the GWAS results suggest a disease-associated chromoso-
mal region, it is still difficult to determine the true disease-causing SNP. The rea-
son is that the functional SNPs that cause disease occur within a gene with a 
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large degree of variability, either in the coding DNA sequence, the splicing site, 
or in the regulatory region of a gene. Even though the association with disease 
found by GWAS is validated, only a few currently believe that these results can 
be used to guide clinical practice in the short term, such as to assess a person’s 
risk of developing a disease. (157) Although GWAS has found many SNPs that 
may be related to disease phenotypes, it is still unclear how these genes interact 
with environmental factors and how lifestyle changes regulate the roles of these 
genes. 
 
2.2. Participants and their genetic information 
The UK Biobank cohort recruited over 500,000 people aged between 40 and 
69 years in 2006–2010 across the UK. Participants completed a detailed clini-
cal, demographic, and lifestyle questionnaire, underwent clinical measures, pro-
vided biological samples (blood, urine and saliva) for future analysis, and 
agreed to have their health records accessed. The informed consent of all par-
ticipants has been obtained. Details of the UK Biobank resource can be found 
at www.ukbiobank.ac.uk. UK Biobank received ethical approval from the Na-
tional Health Service National Research Ethics Service (reference 
11/NW/0382). The current analyses were conducted under approved UK Bi-
obank data application number 4844.The details of genotype quality, properties 
of population structure and relatedness of the genetic data, and efficient phas-
ing and genotype imputation are described by Bycroft, C. et al. (149) 
 
2.3. Phenotypic information on pain 
The UK Biobank participants were offered a pain-related questionnaire, which 
included the question: ‘In the last month have you experienced any of the follow-
ing that interfered with your usual activities?’ The options were: 1. Headache; 2. 
Facial pain; 3. Neck or shoulder pain; 4. Back pain; 5. Stomach or abdominal pain; 
6. Hip pain; 7. Knee pain; 8. Pain all over the body; 9. None of the above; 10. 
Prefer not to say. These body-site pain options were not mutually exclusive, and 
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participants could choose as many as they felt appropriate. The pain all over the 
body cases in this study were those who selected the ‘pain all over the body’ 
option in response to the question, regardless of whether they had selected other 
options. The controls in this study were those who selected the ‘None of the 
above’ option. Thus, the same ‘no pain’ control population was used for all pain 
phenotypes in different body sites. 
 
2.4. Statistical analysis 
The source material was derived from the raw data from the UK Biobank and 
underwent GWAS approaches by BGENIE. (158) In this study, we used BGENIE 
(https://jmarchini.org/bgenie/) to be the main GWAS software and removed single 
nucleotide polymorphism (SNPs) with INFO scores < 0.1, with minor allele fre-
quency < 0.5%, or those that failed Hardy-Weinberg tests P < 10−6. The GWAS 
model was a mixed linear regression model, and the genetic model was additive 
as default. SNPs on sex chromosomes and the mitochondrion as well as imputed 
SNPs that were not in the Haplotype Reference Consortium panel were excluded 
from analyses. Standard Frequentist association tests using BGENIE was used 
to perform association studies adjusting for age, sex, body mass index (BMI), 9 
population principal components, genotyping arrays, and assessment centres. 
The gender difference between cases and controls was compared using chi-
square testing. Age and BMI were compared using independent t testing in IBM 
SPSS 24 (IBM Corporation, New York). SNP associations were considered sig-
nificant if they had a p value < 5 × 10−8. GCTA was used to calculate SNP-based 
or narrow-sense heritability using a genomic relationship matrix calculated from 
genotyped autosomal SNPs. 
 
The main part of the study was to run the GWAS summary on FUMA (Functional 
Mapping and Annotation of Genome-Wide Association Studies, see Figure 2-4), 
a platform that can be used to annotate, prioritize, visualize and interpret GWAS 
results. (159) Compared to other applications for SNP annotation e.g., GWAS4D, 
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SNPnexus, etc., the advantages of FUMA are the consolidation of multifunctional 
mainstream resources of GWAS, continuous updates and timely maintenances, 
and less burden of offline calculation. The operation of FUMA is also simplified, 
for most of the calculations are automatically executed after uploading and sub-
mitting the GWAS file. 
 
Figure 2-4 Flowsheet of the methodology 
 
The SNP2GENE function takes GWAS summary statistics as an input and pro-
vides extensive functional annotation for all SNPs in genomic areas identified by 
lead SNPs. To characterise the significant hits, the SNP2GENE can be broken 
down into three steps (see Figure 2-5)5. The first step is to characterise genomic 
loci, including identifying independent significant SNPs and candidate SNPs, de-
fining leading SNPs, and genomic risk loci. The second step is to annotate can-
didate SNPs in genomic loci, with tests of expression quantitative trait loci (eQTL), 
15 chromatine state, 3D chromatine interactions (Hi-C), etc. The third step is to 
generate the table of functional gene mapping, which is used in GENE2FUNC, 
another main process of FUMA. The interact visualisation (Manhattan plot, etc) 
is based on the results from all three steps, with p-values calculated by MAGMA 
 
5 From https://fuma.ctglab.nl/tutorial 
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(Multi-marker Analysis of GenoMic Annotation, integrated in FUMA) gene analy-
sis and MAGMA gene-set analysis (GSA). GSA makes genes be aggregated into 
gene sets on the basis of shared biological or functional properties according to 
certain knowledge bases. Knowledge bases are database collections of molecu-
lar knowledge that may encompass molecular interactions, regulation, molecular 
products and even phenotype associations. The resultant gene sets are analysed 
as a whole to determine which of these properties are relevant to the phenotype 
of interest. GSA is able to generate hypotheses on phenomenalistic processes 
for the phenotypes of interest, and the replication and laboratory experiments 
should also be done to validate the results. (160, 161) The MHC region was ex-
cluded from the analysis, and SNPs in that region were not annotated. 
 
Figure 2-5 Basic functions of SNP2GENE of FUMA 
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3. Results 
3.1. GWAS results 
There were 872,316 items of completed records in response to the question of 
‘pain type(s) experienced last month’ in the questionnaire, covering 501,600 pa-
tients. Among these patients, 9,551 reported having experienced activity-limiting 
pain all over the body in the previous month. There were 232,467 participants 
who selected ‘none of the above’ option, which meant that they did not have any 
form of pain that limited the activity in the previous month. 
 
Firstly, samples were checked to establish a homogeneous dataset. Ancestry in-
formation provided from the UK Biobank was used in the process. In addition, 
those who were related to one or more in the cohort (a cut-off value of 0.044 (162, 
163) in the generation of the genetic relationship matrix) and those who failed 
quality control were also removed. After the exclusions (see Figure 3-1), the num-
ber in the case group fell to 5,670 (2,171 males vs 3,499 females, see Figure 3-
1). Meanwhile, the control group encompassed 149,312 (71,480 males, 77,832 
females) individuals. After the quality control of SNPs, 9,304,965 SNPs were 
available for the GWAS. Clinical characteristics of the cases and controls were 
compiled (Table 3-1). Age, sex, and BMI were all found to be significantly different 
(p < 0.01) between cases and controls.  
 
A quantile-quantile plot (Q-Q plot) can be used to characterise the extent to which 
the observed distribution of the test statistic follows the expected distribution. In 
GWAS, the null hypothesis is that none of the SNPs in the test is related to the 
certain disease. With the null hypothesis, the P values from the tests where no 
true association exists should follow a continuous uniform distribution. The devi-
ation at the tail of the Q-Q plot can deny the null hypothesis. Q-Q plot can be a 




With a threshold of p < 5×10-8, two genetic loci including three significant and 
independent SNPs were found in the GWAS (Figure 3-2, Table 3-2). The most 
significant SNP (rs550883786, p = 1.69×10-8) was found in an intergenic region 
in chromosome 4. The first locus was found in the FAF1 gene located in chromo-
some 1, and the most significant SNP from this locus was rs17387024 (p = 
3.72×10-8). The second locus was the LINC01078 (long intergenic non-protein 
coding RNA 1078) gene located in chromosome 13, and the most significant SNP 
in this locus was rs148500993 (p = 3.65×10-8). The highest peak shown in the 
Manhattan plot was in chromosome 6, but there were no significant SNPs anno-
tated in that area, and no SNPs in chromosome 6 were recorded in FUMA results 
files. Due to the fact that the LD among SNPs was very complicated in this area, 
FUMA does not annotate this region by default as most of the FUMA related anal-
yses (such as MAGMA) was based on the correctness of LD. (159) Besides, no 




Figure 3-1 Original & adjusted statistics of cases & controls in the UK Biobank 
 
 
Table 3-1 Genders, ages and BMIs of cases and controls of CWP6 
Covariates Cases Controls p-value 





Age (years) 57.3 (7.59) 56.9 (7.97) 0.002 
BMI (Body mass index, kg/m2) 29.6 (5.96) 26.7 (4.30) < 0.001 
 
6 The chi-square test was used for gender frequency between cases and controls, while Student t-tests 
were used for others. Continuous covariates were presented as mean (standard deviation). 
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Table 3-2 The summary statistics of the three significant and independent SNPs 
rsID chr position start end p-value (10-8) allele1:allele2 nSNPs nGWASSNPs Related gene 
rs17387024 1 50993178 50993178 51476972 3.72 C:T 6 6 FAF1 
rs550883786 4 29485633 28609064 30094647 1.69 C:T 12 1 (intergenic region) 
rs148500993 13 75823871 74987745 76754250 3.65 C:G 9 2 LINC01078 
 
 
Table 3-3 The significant gene sets with Bonferroni p value < 0.05. 
Standard gene-set name Systematic name Category Number of genes β β SD p-value (×10-6) Bonferroni p-value 
davicioni_targets_of_pax_foxo1_fusions_up M4680 Curated 243 0.283 0.032 1.29 0.0200 
missiaglia_regulated_by_methylation_up M12272 Curated 112 0.356 0.027 2.33 0.0360 
go_structural_constituent_of_synapse M26829 Ontology 14 1.072 0.029 2.67 0.0413 





Figure 3-3 The Q-Q plot of GWAS summary statistics7  
 
 





7 For plotting purposes, overlapping data points are not drawn. Lambda= 1.09  
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The Q-Q plots (Figure 3-3 and 3-4) were generated to complement the results 
shown in Manhattan plot. The observed p-values at the extreme deviated from 
the expected null distribution (uniform distribution), which suggested possible un-
adjusted covariates between cases and controls. 
 
3.2. FUMA results 
In gene-based association analysis by MAGMA (integrated into FUMA), a total of 
10,894 gene sets were tested and a default competitive test model was applied. 
Eight genes were found to be associated with CWP (Figures 3-4 & 3-5). The most 
significant gene was MRPL44 (P = 1.30×10-8) located at chromosome 2. The 
genes found in the gene-based test were located in completely different chromo-
somes compared with the significant and independent SNPs found in GWAS. 
 
In gene-set analysis conducted by MAGMA, 15,496 gene-sets were analysed 
using the default competitive test model. Gene sets of positive regulation of gene 
expression, positive regulation of transcription from RNA polymerase II promoter, 
neurogenesis, and excitatory synapse reached a P value < 0.0001, but not sta-
tistically significant of p < 5×10−6 (0.05/10,894). The top four gene-sets met ge-
nome-wide significance and were included in Table 3-3. 
 
Tissue expression analysis was conducted by GTEx (Genotype-Tissue Expres-
sion), and the relationship between tissue-specific gene expression and genetic 
associations was tested by using the average gene expression in each certain 
tissue type as a covariate. Two analyses were carried out. One investigated 30 
general tissue types (Figure 3-6) and the other focused on 53 specific tissue types 
(Figure 3-7). Tissue expression analysis in 30 tissue types did not find significant 
expression in any of the tissue types. Tissue expression analysis of 53 specific 
tissue types by GTEx found that the expression in the cerebellar hemisphere had 
the lowest p value (p = 1.03×10-3), and the expressions in other parts of brain 
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such as cerebellum, cortex, and frontal cortex BA9 also had relatively low p-val-
ues, but none of them reached the significant p value, either. 
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Figure 3-5 The Manhattan plot of the gene-based test as computed by MAGMA based on the input GWAS summary statistics8 
 
8 Genome wide significance (red dashed line in the plot) is defined at p = 0.05/19043 = 2.626×10-6. 
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Figure 3-6 Tissue expression results on 30 specific tissue types by GTEx in the FUMA9 
 
 
9 The blue columns indicate that they do not reach the cut-off p-value for significance with Bonferroni adjustment for multiple hypothesis testing. 
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Figure 3-7 Tissue expression results on 53 specific tissue types by GTEx in the FUMA10 
 
 
10 The dashed line shows the cut-off p-value for significance with Bonferroni adjustment for multiple hypothesis testing 
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4. Discussion 
4.1. Lead SNPs and related genomic loci 
We have derived three loci which reached the genome-wide significance (p < 
5×10-8) from this GWAS on pain over the body with the resources from the UK 
Biobank. They are respectively located at the FAF1 gene in chromosome 1, an 
intergenic region in chromosome 4 and the LINC01078 gene in chromosome 13. 
 
In this study, we defined the term ‘pain all over the body’ based on the responses 
of the participants from the UK Biobank. The generic pain question generated by 
the UK Biobank is a useful implement for testing whether a heterogeneous pain 
phenotype (e.g., neck and shoulder pain, knee pain, pain all over the body, etc.) 
has genetic components in nature or not. For instance, Meng et al. used the same 
question as an identification of the genetic variants of broadly defined headache, 
and their findings basically tallied with other researches in well-defined migraine 
phenotypes. (164, 165) One of the advantages to use the UK Biobank on heter-
ogeneous phenotypes is that researchers are able to use large numbers to re-
duce statistical noise, and they can compensate for potentially reduced power 
because of heterogeneity.  
 
The top locus is at the intergenic region in chromosome 4 with the lowest p value 
of 1.69×10-8 for rs550883786, and there is one lead SNP as well as 11 other 
unique candidate SNPs (known as nIndSigSNPs) in the genomic locus. The sec-
ond locus is at the LINC01078 gene in chromosome 13 with the second lowest p 
value of 3.65×10-8 for rs17387024, and there are two GWAS-tagged candidate 
SNPs out of nine unique candidate SNPs in the genomic locus. The LINC01078 
gene is a gene with 441 nt (nucleotides) which codes RNA 1078 rather than any 
sorts of proteins11. There have been no publications about this gene to date. Its 
nearest gene which encodes a protein is the TBC1D4 gene (see Figure 4-1), with 
 
11 See https://www.genecards.org/cgi-bin/carddisp.pl?gene=LINC01078 
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a length of 199,642 nt. TBC1D4, also named as AS160 (Akt substrate of 160 kDa), 
is the Rab-GTPase-activating protein. Researches have revealed that TBC1D4 
plays an important role in the homoeostasis of glucose with the regulation of in-
sulin-dependent trafficking of the glucose transport type 4 (GLUT-4, also known 
as solute carrier family 2), which helps to remove glucose from the bloodstream 
to fat tissues and skeletal muscle. (166, 167) When exposed to insulin, this pro-
tein is phosphorylated, dissociates from GLUT4 vesicles, resulting in increased 
GLUT4 at the cell surface, and enhanced glucose transport. In spite of the pivotal 
role of TBC1D4 in the pathophysiology of diabetes, the features, and functions of 
TBC1D4 seem to be irrelevant to the mechanisms of either FM or CWP, and no 
connection can be established between the TBC1D4 gene and the phenotype 
‘pain all over the body’. 
 
Figure 4-1 Locations of LINC01078 and TBC1D4 gene in chromosome 1312 
 
 
Figure 4-2 Location of FAF1 gene in chromosome 113 
 
The final locus is at the FAF1 gene in chromosome 1p32.3 (see figure 4-2) with 
the third lowest p value of 3.72×10-8 for rs17387024. rs17387024 is the lead 
SNPs in the genomic locus, while the number of GWAS-tagged SNPs which are 
in LD of the independent significant SNPs given r2 (known as nGWASSNPs) is 
six. The length of FAF1 gene is 523,240 nt and the gene encodes the protein 
 
12 Screenshot from https://www.ncbi.nlm.nih.gov/snp/rs148500993 
13 Screenshot from https://www.genecards.org/cgi-bin/carddisp.pl?gene=FAF1 
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named fas-association factor 1 (FAF1). The protein contains 650 amino acids 
with a mass of 73,954 Da. Initially identified as a Fas-binding protein, FAF1 was 
found to increase the likelihood of Fas-induced apoptosis.(168) The functions of 
FAF1 are various and it takes part in multiple mechanisms which promote cell 
death (see Table 4-2). It exerts influence on both extrinsic and intrinsic pathways 
and mediates the activation of caspase 8. (169) FAF1 can also suppress the ac-
tivation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
by interfering IKK (IκB kinase) complex assembly, and the lowered complex for-
mation is related with physical interaction with IKKβ. (170) The negative feedback 
regulation of Aurora-A via phosphorylation of FAF1 is also supported, which clar-
ifies one of the intermediate links of cell cycle. (171) Besides, the interactions 
between FAF1 and VCP (valosin-containing protein, as known as transitional en-
doplasmic reticulum adenosine triphosphatase, TER ATPase) have been found 
to inhibit the ubiquitin dependent protein degradation. (172) The downregulation 
of FAF1 has been observed in gastric and uterine cervix carcinomata, and thus it 
is thought to function as one of the tumour suppressors through the activities in 
promotion of apoptosis. (173, 174) 
 
Along with its suppressive roles in the development of tumour, FAF1 is found to 
be involved in the pathogenesis of Parkinson’s disease (PD). Betarbet et al. found 
a significant increase of FAF1 expression in the prefrontal cortices of patients with 
PD, and FAF1 enlarges the toxic effects of stressors related to PD, such as oxi-
dative stress. (175) Furthermore, as a pathogenic substrate of parkin, a ubiquitin 
E3 ligase, FAF1 plays a determining role in the dopaminergic neural degeneration: 
the inactivation of parkin by PD-linked mutations or by genetic deletion causes 
the uplifted expression FAF1 and other relevant biochemical reactions mediated 
by it. The influenced events in animal models encompass caspase activation, 
ROS (reactive oxygen species) generation, JNK (c-Jun N-terminal kinase) acti-
vation and cell death. (176) The related experiments imply that the pathogenesis 
of PD and the oxidative stress-induced cell death pivot on the action of FAF1 on 
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the apoptotic mechanism. FAF1 is also involved in the pathogenesis of ischemic 
diseases. Yu et al. established a retinal ischemia model and found that FAF1 was 
a key factor of JNK1-dependent necrosis upon ischemic stress, which was fol-
lowed by mitochondrial dysregulation. (177)  
 
The finding of the FAF1 gene that is genetically associated with the phenotype 
‘pain all over the body’ coincides with another GWAS of multisite chronic pain 
(MCP) in the UK Biobank. (94) Apart from FAF1 gene, the study also found that 
38 other genomic risk loci, and 76 independent genome-wide significant SNPs 
associated with MCP were identified in total, which was a lot more fruitful. Alt-
hough MCP, CWP, and pain all over the body are all subsets of chronic pain, 
these phenotypes are slightly different by definition. MCP stresses the number of 
sites at which chronic pain is experienced. According to the UK Biobank ques-
tionnaire (field ID 6159), seven individual body-site pain options were not mutu-
ally exclusive, and participants could choose more than one answer, except for 
those who chose ‘pain all over the body’, ‘none of the above’ or ‘prefer not to say’.  
MCP was defined as the sum of body sites at which chronic pain (at least 3 
months duration) was recorded: 0 to 7 sites, based on an additional question in 
UK Biobank (Category 100048). Those who answered that they had chronic pain 
‘all over the body’ were excluded from the GWAS.
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Table 4-2 FAF1 protein reactions (adopted from Craig W. Menges) 
Interaction(s) Function(s) Method(s) of detection 
TNFRSF6 (tumour necrosis factor receptor su-
perfamily member 6) 
Regulation of apoptosis Yeast two-hybrid screening and overexpression in mouse L cells; 
overexpression in human BOSC23 cells (168, 169) 
Fas-associated protein with death domain 
(FADD/MORT1) and caspase 8 
Co-immunoprecipitation, co-localization, and overexpression in 
Jurkat cells (169) 
Protein kinase casein 
kinase 2 beta 
(CK2beta) 
Yeast two-hybrid; immunoprecipitation and co-localisation studies 
(178, 179) 
nuclear factor NF-kappa-B p65 subunit Inhibition of NF-κB by cytoplasmic retention of 
p65 
Overexpression and immunoprecipitation studies in HEK-293 and 
NIH3T3 cells (180) 
IKK (IκB kinase) Suppression of IKK activation linked to regula-
tion of NF-κB 
Immunoprecipitation, overexpression and siRNA studies in 
HEK293 cells (170) 




Inflammatory signalling associated with NF-κB Yeast two-hybrid screen, immunoprecipitation, and co-expression 
in HEK 293 and HEK293T cells (181) 
Ubiquitinated proteins and valosin-containing 
protein (VCP) 
Regulation of protein degradation in the ubiqui-
tin-proteasome pathway 
Overexpression in HEK293T cells; protein dissociation of rat skel-
etal muscle and mass spectrometry (108, 172) 
Heat shock protein 70 (Hsp70) Inhibition of Hsp70 chaperone of refolding dena-
tured protein substrates 
Co-immunoprecipitation, peptide mass fingerprinting, and co-lo-
calization in HEK293T cells (182) 
Mineralocorticoid receptor (MR) and Modulates transactivation potential; selectively Yeast two-hybrid screening and co-expression in HN9.10 mouse 
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Interaction(s) Function(s) Method(s) of detection 
glucocorticoid receptor (GR) stimulates MR-mediated transcription hippocampal cells (183) 
Transient receptor potential vanilloid 1 recep-
tor (TRPV1) 
Modulates sensitivity to noxious stimuli (capsai-
cin, acid, heat) in sensory neurons 
Co-expression and immunoprecipitation from sensory neurons or 
HEK293T cells (184) 
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4.2. Gene-set analysis 
Four gene-sets were found significant according to the analysis by MAGMA. 
However, there is little connection between the found gene-sets and FM/CWP. 
The most significant gene set M4680 was briefly described as Genes up-regu-
lated in RD cells (embryonal rhabdomyosarcoma, ERMS) by expression of PAX3- 
or PAX7-FOXO1 [GeneID=5077;5081;2308] fusions off retroviral vectors. (185) 
Gene set M12272 was briefly described as genes up-regulated in PaCa44 and 
CFPAC1 cells (pancreatic cancer) after treatment with decitabine [Pub-
Chem=451668], a DNA hypomethylating agent similar to azacitidine [Pub-
Chem=9444]. (186) The other two gene-sets are lack of enough publications to 
reveal their relationship with FM/CWP. 
 
4.3. Limitations in the study 
It could be a drawback that the phenotype was based on answers by participants’ 
self-reporting. However, the sample size was large enough so it should have suf-
ficient power to identify genetic factors related to pain all over the body. Although 
the observational studies have shown that females are more likely to have symp-
toms of FM compared to males, the study did not include any genes on sex chro-
mosomes. Thus, the genomic relationship between gender and FM/CWP was not 
able to be revealed. It could also cause biases because of different criteria of 
timespan, as the questionnaire is concerned about only one month. 
 
According to the Manhattan plot, the most significant SNP should have been lo-
cated in chromosome 6, but the algorithm excluded the MHC region and no sig-
nificant SNPs in chromosome 6 were included in the output, which could be an-
other limitation. 
 
The Q-Q plot suggested that there could be residual confounding factors between 
cases of pain all over the body and controls that have not been adjusted for. 
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Replication of the study is also difficult owing to the fact that the nature of chronic 
pain phenotyping is not unanimous and available cohort sizes are not always 
consistent. Nevertheless, there are resemblances among identified genomic risk 
loci in other GWA studies in complex traits pertaining to chronic pain, including 
chronic back pain, migraine, and FM, etc. There was only one gene of interest 




Pain all over the body is one of the subsets of pain, and it is the complement to 
other phenotypes of pain in specific regions (headache, knee pain, neck and 
shoulder pain, etc). The study revealed part of the genomic traits of this pheno-
type by using the UK Biobank. It is the first research to explore the genetic factors 
of pain all over the body. The study suggested that the FAF1 gene could be re-
lated to pain all over the body, along with cell-cycle and programmed cell death, 
and the expression was primarily within brain tissues. The results conformed with 
other genetic and neurological chronic pain studies in which functional and struc-
tural alternations of the brain were found to contribute to chronic pain. (187, 188) 
This study could be a valuable supplement to the studies in other pain pheno-
types in the UK Biobank. The study may also compare with further studies in pain 
phenotypes with similar definitions (e.g., multisite chronic pain, widespread 
chronic pain, etc.). Further studies should also encompass sex chromosomes to 
uncover the genomic relationship between sex and fibromyalgia/chronic wide-
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Appendices 
Appendix 1 All SNPs in LD with any of independent lead SNPs with r2 greater or equal to the defined threshold (part 1) 




MAF gwasP (10-8) beta 
(10-3) 
SE (10-4) r2 IndSigSNP 
1:50993178:C:T rs17387024 1 50993178 C T 0.1481 3.71706366796 5.1885 9.4266 1 rs17387024 
1:51128777:A:G rs10493152 1 51128777 G A 0.17 15.8379876507 4.6495 8.8684 0.828505 rs17387024 
1:51142556:C:T rs17384367 1 51142556 C T 0.09841 5.67022118161 6.1356 11.301 0.617949 rs17387024 
1:51161263:A:G rs78884406 1 51161263 A G 0.1481 13.2342702837 4.8930 9.2744 0.967178 rs17387024 
1:51264933:C:T rs78091876 1 51264933 C T 0.1511 25.4448561515 4.8493 9.4077 0.959427 rs17387024 
1:51476972:C:T rs77094699 1 51476972 T C 0.1441 251.420103016 4.6284 9.8326 0.870554 rs17387024 
4:28609064:A:C rs573680863 4 28609064 C A 0.000994 NA NA NA 1 rs550883786 
4:28641266:A:T rs529928586 4 28641266 T A 0.000994 NA NA NA 1 rs550883786 
4:28705788:C:G rs531292161 4 28705788 C G 0.000994 NA NA NA 1 rs550883786 
4:28936170:A:C rs530516790 4 28936170 A C 0.000994 NA NA NA 1 rs550883786 
4:28937541:C:T rs567598400 4 28937541 C T 0.000994 NA NA NA 1 rs550883786 
4:29047725:A:C rs112223043 4 29047725 A C 0.000994 NA NA NA 1 rs550883786 
4:29094291:C:T rs535479714 4 29094291 C T 0.000994 NA NA NA 1 rs550883786 
4:29096073:C:G rs571597976 4 29096073 C G 0.000994 NA NA NA 1 rs550883786 
4:29436739:C:T rs531324916 4 29436739 C T 0.000994 NA NA NA 1 rs550883786 
4:29485633:C:T rs550883786 4 29485633 T C 0.000994 1.68655302539 82.379 0.014602 1 rs550883786 
4:29807162:A:G rs571291698 4 29807162 A G 0.000994 NA NA NA 1 rs550883786 
4:30094647:C:G rs184775812 4 30094647 C G 0.000994 NA NA NA 1 rs550883786 
13:74987745:C:T rs184775812 13 74987745 C T 0.000994 NA NA NA 1 rs148500993 
13:75032941:G:T rs566173881 13 75032941 G T 0.000994 NA NA NA 1 rs550883786 
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MAF gwasP (10-8) beta 
(10-3) 
SE (10-4) r2 IndSigSNP 
13:75185289:C:T rs564356221 13 75185289 T C 0.000994 NA NA NA 1 rs148500993 
13:75220378:C:T rs148567855 13 75220378 C T 0.000994 NA NA NA 1 rs550883786 
13:75288942:A:G rs542414084 13 75288942 G A 0.000994 NA NA NA 1 rs148500993 
13:75477615:G:T rs563178847 13 75477615 T G 0.000994 NA NA NA 1 rs148500993 
13:75823871:C:G rs148500993 13 75823871 C G 0.000994 3.64753946926 63.324 114.98 1 rs148500993 
13:75873067:G:T rs562398442 13 75873067 T G 0.000994 31.564578913 57.674 112.77 1 rs148500993 
13:76754250:C:T rs550007917 13 76754250 C T 0.000994 NA NA NA 1 rs148500993 
uniqID: Unique ID of SNPs consists of chr:position:allele1:allele2 where alleles are alphabetically ordered. 
rsID: rsID based on dbSNP build 146. 
chr: Chromosome 
pos: Position on hg19 
effect allele: Effect/risk allele if it is provided in the input GWAS summary statistics file. If not, this is the alternative (minor) allele in 1000G. 
non-effect allele: Non-effect/non-risk allele if it is provided in the input GWAS summary statistics file. If not, this is the reference (major) allele in 1000G. 
MAF: Minor allele frequency computed based on 1000G. 
gwasP: P-value provided in the input GWAS summary statistics file. Non-GWAS tagged SNPs (which do not exist in input file but are extracted from the reference 
panel) have ‘NA’ instead. 
beta: Beta provided in the input GWAS summary statistics file if available. Non-GWAS tagged SNPs (which do not exist in input file but are extracted from the 
reference panel) have ‘NA’ instead. 
SE: Standard error provided in the input GWAS summary statistics file if available. Non-GWAS tagged SNPs (which do not exist in input file but are extracted from 
the reference panel) have ‘NA instead. 
r2: The maximum r2 of the SNP with one of the independent significant SNP (this doesn't have to be top lead SNPs in the genomic loci). 
IndSigSNP: rsID of an independent significant SNP which has the maximum r2 of the SNP. 
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Appendix 2 All SNPs in LD with any of independent lead SNPs with r2 greater or equal to the defined threshold (part 2) 
uniqID genomic 
locus 






1:50993178:C:T 1 FAF1 0 intronic 13.92 2b 2 5 1 0 0 
1:51128777:A:G 1 FAF1 0 intronic 2.789 6 5 15 1 0 0 
1:51142556:C:T 1 FAF1 0 intronic 1.043 6 5 15 1 0 0 
1:51161263:A:G 1 FAF1 0 intronic 3.298 6 5 15 1 0 0 
1:51264933:C:T 1 FAF1 0 intronic 9.294 7 5 15 1 0 0 
1:51476972:C:T 1 FAF1 0 intronic 4.161 5 9 15 0 0 0 
4:28609064:A:C 2 RP11-123O22.1 7166 intergenic 0.04 NA 5 15 0 0 0 
4:28641266:A:T 2 RP11-123O22.1 39368 intergenic 8.69 NA 5 15 0 0 0 
4:28705788:C:G 2 RN7SL101P 7031 intergenic 2.049 NA 5 15 0 0 0 
4:28936170:A:C 2 RP11-292B1.2 61975 intergenic 3.008 NA 9 15 0 0 0 
4:28937541:C:T 2 RP11-292B1.2 60604 intergenic 0.681 NA 9 15 0 0 0 
4:29047725:A:C 2 RP11-769N22.1 487 upstream 2.63 6 5 15 0 0 0 
4:29094291:C:T 2 RP11-472K22.1 25638 intergenic 0.588 NA 9 15 0 0 0 
4:29096073:C:G 2 RP11-472K22.1 23856 intergenic 1.162 NA 7 15 0 0 0 
4:29436739:C:T 2 RP11-68D16.1 27104 intergenic 0.24 NA 9 15 0 0 0 
4:29485633:C:T 2 RP11-68D16.2 16160 intergenic 0.987 NA 9 15 0 0 0 
4:29807162:A:G 2 AC109351.1 55229 intergenic 0.337 NA 1 15 0 0 0 
4:30094647:C:G 2 RP11-174E22.2 84708 intergenic 0.289 NA 5 15 0 0 0 
13:74987745:C:T 3 AL355390.1 0 UTR3 0.052 7 5 15 1 0 0 
13:75032941:G:T 3 LINC00381 23644 intergenic 0.368 NA 9 15 0 0 0 
13:75185289:C:T 3 LINC00347 45706 intergenic 2.169 NA 9 15 0 0 0 










13:75288942:A:G 3 RIOK3P1 113747 intergenic 4.54 NA 5 15 0 0 0 
13:75477615:G:T 3 RIOK3P1 73397 intergenic 8.447 NA 5 15 0 0 0 
13:75823871:C:G 3 LINC01078 744 upstream 2.942 6 5 15 0 0 0 
13:75873067:G:T 3 TBC1D4 0 intronic 0.197 NA 4 5 1 0 0 
13:76754250:C:T 3 RN7SL571P 44889 intergenic 0.633 NA 14 15 0 0 0 
genomic locus: Index of the genomic risk loci matching with “GenomicRiskLoci.txt”. 
nearest gene: The nearest Gene of the SNP based on ANNOVAR annotations. 
 Note that ANNOVAR annotates "consequence" function by prioritising the most deleterious annotation for SNPs which are locating a genomic region where 
multiple genes are overlapped. 
 Genes are encoded in symbol, if it is available, otherwise Ensembl ID. 
 Genes include all transcripts from Ensembl gene build 85 including non-protein coding genes and RNAs. 
dist : Distance to the nearest gene. SNPs which are locating in the gene body or 1kb up- or down-stream of TSS or TES have 0. 
func : Functional consequence of the SNP on the gene obtained from ANNOVAR. For exonic SNPs, detail annotation (e.g., non-synonymous, stop gain and so on) 
is available in ANNOVAR table (annov.txt). 
CADD : CADD score which is computed based on 63 annotations. The higher score, the more deleterious the SNP is. 12.37 is the suggested threshold by Kicher 
et al (2014). 
RDB: RegulomeDB score which is the categorical score (from 1a to 7). 1a is the highest score that the SNP has the most biological evidence to be regulatory 
element. 
minChrState : The minimum 15-core chromatin state across 127 tissue/cell type. 
commonChrState : The most common 15-core chromatin state across 127 tissue/cell types. 
posMapFilt: Whether the SNP was used for positional mapping or not. 1 is used, otherwise 0. When positional mapping is not performed, all SNPs have 0. 
eqtlMapFilt: Whether the SNP was used for eqtl mapping or not. 1 is used, otherwise 0. When eQTL mapping is not performed, all SNPs have 0. 
 
